Beranda › Hemofilia B
Uji klinis Hemofilia B yang merekrut di AS
12 studi untuk Hemofilia B merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Philadelphia, PA5 studi
- Sacramento, CA4 studi
- Ann Arbor, MI4 studi
- Atlanta, GA4 studi
- Houston, TX4 studi
- Los Angeles, CA4 studi
- Seattle, WA3 studi
- San Francisco, CA3 studi
- Indianapolis, IN3 studi
- Gainesville, FL3 studi
- Nashville, TN3 studi
- Greenville, NC3 studi
Berdasarkan negara bagian
- California7 studi
- Florida4 studi
- Georgia4 studi
- Indiana3 studi
- Louisiana3 studi
- Michigan6 studi
- Missouri3 studi
- New York5 studi
- North Carolina4 studi
- Ohio3 studi
- Pennsylvania6 studi
- Tennessee4 studi
- Texas4 studi
- Washington3 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Menerima pesertaFase 3
Usia 18 ke atas · Pria · Diperbarui 2 Okt 2026 · NCT05568719A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Menerima pesertaFase 3
Usia 1 hingga 17 · Pria · Diperbarui 23 Sep 2026 · NCT05611801Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Menerima pesertaFase 3
138 Months – 206 Months · Pria · Diperbarui 16 Sep 2026 · NCT07080905A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Menerima pesertaFase 1/2
Usia 2 ke atas · Pria · Diperbarui 11 Sep 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06003387SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Menerima pesertaFase 3
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT04563520ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Menerima pesertaFase 3
Usia 1 hingga 74 · Pria · Diperbarui 1 Jul 2026 · NCT05145127ATHNdataset Registry
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 21 Apr 2026 · NCT06820515An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT06008938SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Menerima pesertaFase 4
Usia 12 hingga 100 · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT04647227Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.